Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Feature | Antiplatelet and Anticoagulation Therapies

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first ...

Home May 07, 2018
Home
Technology | Clinical Decision Support

April 30, 2018 — Point of Care Decision Support (PCDS) announced the release of a new version 2.0 of their ...

Home April 30, 2018
Home
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18
Feature | ACC | Dave Fornell

There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American College ...

Home March 27, 2018
Home
News | ACC

March 22, 2018 — The experimental drug andexanet was associated with control of serious bleeding in patients taking a ...

Home March 22, 2018
Home
News | ACC

March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart attack ...

Home March 20, 2018
Home
News | ACC

March 20, 2018 — Among people younger than 75 years who were given clot busters to treat a heart attack, taking the more ...

Home March 20, 2018
Home
News | ACC

March 20, 2018 — When patients who had a heart attack were given vouchers to cover their co-payments for medication to ...

Home March 20, 2018
Home
News | ACC

March 20, 2018 — Patients with acute coronary syndrome experienced a substantially lower rate of heart attack, stroke ...

Home March 20, 2018
Home
News | Antiplatelet and Anticoagulation Therapies

March 19, 2018 — The combined rate of death from any cause, heart attack or stroke within 18 months was not ...

Home March 19, 2018
Home
News | ACC

March 15, 2018 — For people living with both Type 2 diabetes and heart failure, taking an aspirin each day appears to ...

Home March 15, 2018
Home
News | Antiplatelet and Anticoagulation Therapies

March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiology ...

Home March 14, 2018
Home
News | ACC

March 13, 2018 –  Among patients with persistently high cholesterol despite high-intensity statin therapy, the ...

Home March 13, 2018
Home
News | Antiplatelet and Anticoagulation Therapies

February 19, 2018 — A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International ...

Home February 19, 2018
Home
News | Antiplatelet and Anticoagulation Therapies

February 13, 2018 — Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual ...

Home February 13, 2018
Home
Technology | Antiplatelet and Anticoagulation Therapies

January 22, 2018 — Baxter International Inc. announced the U.S. Food and Drug Administration (FDA) approval of ...

Home January 22, 2018
Home
Subscribe Now